UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research

Nature reviews. Microbiology, 2019-04, Vol.17 (4), p.203-218

2019

Volltextzugriff (PDF)

Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management

Clinical microbiology reviews, 2015-07, Vol.28 (3), p.603-661

2015

Volltextzugriff (PDF)

Contribution of urinary tract infection to the burden of febrile illnesses in young children in rural Kenya

PloS one, 2017-03, Vol.12 (3), p.e0174199

2017

Volltextzugriff (PDF)

Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial

Trials, 2022-05, Vol.23 (1), p.407-15, Article 407

2022

Volltextzugriff (PDF)

Surveillance of iclaprim activity: in vitro susceptibility of Gram-positive skin infection pathogens collected from 2015 to 2016 from North America and Europe

Diagnostic microbiology and infectious disease, 2019-02, Vol.93 (2), p.154-158

2019

Volltextzugriff (PDF)

Clinical management of Staphylococcus aureus bacteremia: a review

JAMA : the journal of the American Medical Association, 2014-10, Vol.312 (13), p.1330

2014

Volltextzugriff (PDF)

Early Oral Antibiotic Switch for Staphylococcus aureus Bacteremia: Many Are Called, but Few Are Chosen

Antimicrobial agents and chemotherapy, 2020-06, Vol.64 (7)

Holland, Thomas L

2020

Volltextzugriff (PDF)

Evidence-Based Guidelines Should Be Used To Inform COVID-19 Management

Antimicrobial agents and chemotherapy, 2021-02, Vol.65 (3)

Holland, Thomas L

2021

Volltextzugriff (PDF)

Bacteremia Caused by Kerstersia gyiorum

Journal of clinical microbiology, 2015-06, Vol.53 (6), p.1965-1967

2015

Volltextzugriff (PDF)

Which trial do we need? Percutaneous mechanical aspiration versus medical management alone for treatment of right-sided valvular infective endocarditis

Clinical microbiology and infection, 2024-06, Vol.30 (6), p.703-706

2024

Volltextzugriff (PDF)

Practical application of good participatory practices for trials of emerging pathogens: Developing materials for use in ACTIV-3, -3b, and ACTIV-associated COVID-19 trials

Journal of clinical and translational science, 2024-01, Vol.8 (1), Article e157

2024

Volltextzugriff (PDF)

Persistent Methicilin-Resistant Staphylococcus aureus Bacteremia: Resetting the Clock for Optimal Management

Clinical infectious diseases, 2022-10, Vol.75 (9), p.1668

2022

Volltextzugriff (PDF)

Ceftobiprole for Staphylococcus aureus Bacteremia. Reply

The New England journal of medicine, 2023-12, Vol.389 (26), p.2498-2499

2023

Volltextzugriff (PDF)

Antiplatelet Therapy in Staphylococcus aureus Bacteremia: No Time Like the Past?

Antimicrobial agents and chemotherapy, 2022-05, Vol.66 (6), p.e0036522-e0036522

2022

Volltextzugriff (PDF)

Determination of plasma protein binding of dalbavancin

Journal of antimicrobial chemotherapy, 2022-06, Vol.77 (7), p.1899-1902

2022

Volltextzugriff (PDF)

Compiling Observational Research During a Pandemic: A Necessary Bridge

Clinical infectious diseases, 2021-06, Vol.72 (11), p.e750-e752

2021

Volltextzugriff (PDF)

Infective endocarditis

Nature reviews. Disease primers, 2016-09, Vol.2 (1), p.16059-16059, Article 16059

2016

Volltextzugriff (PDF)

Leadless pacemaker infective endocarditis: a case report and review of the literature

Clinical microbiology and infection, 2024-09, Vol.30 (9), p.1199-1201

2024

Volltextzugriff (PDF)

A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study)

Antimicrobial agents and chemotherapy, 2018-05, Vol.62 (5)

2018

Volltextzugriff (PDF)

Combination Therapy for MRSA Bacteremia: To ß or Not to ß?

Clinical infectious diseases, 2020-06, Vol.71 (1), p.11-13

2020

Volltextzugriff (PDF)

Which trial do we need? Next-generation sequencing to individualize therapy in Staphylococcus aureus bacteraemia

Clinical microbiology and infection, 2023-08, Vol.29 (8), p.955-958

2023

Volltextzugriff (PDF)

External Validation of the 2023 Duke–International Society for Cardiovascular Infectious Diseases Diagnostic Criteria for Infective Endocarditis

Clinical infectious diseases, 2024-04, Vol.78 (4), p.922-929

2024

Volltextzugriff (PDF)

Improving Traditional Registrational Trial End Points: Development and Application of a Desirability of Outcome Ranking End Point for Complicated Urinary Tract Infection Clinical Trials

Clinical infectious diseases, 2023-02, Vol.76 (3), p.e1157-e1165

2023

Volltextzugriff (PDF)

Clinical outcomes in patients with piperacillin/tazobactam-non-susceptible but ceftriaxone-susceptible E. coli or K. pneumoniae bloodstream infection

Journal of antimicrobial chemotherapy, 2024-06, Vol.79 (6), p.1456

2024

Volltextzugriff (PDF)

1 – 25 von 764

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(698)
Mit Volltextzugriff
(667)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research

Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management

Contribution of urinary tract infection to the burden of febrile illnesses in young children in rural Kenya

Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial

Surveillance of iclaprim activity: in vitro susceptibility of Gram-positive skin infection pathogens collected from 2015 to 2016 from North America and Europe

Clinical management of Staphylococcus aureus bacteremia: a review

Early Oral Antibiotic Switch for Staphylococcus aureus Bacteremia: Many Are Called, but Few Are Chosen

Evidence-Based Guidelines Should Be Used To Inform COVID-19 Management

Bacteremia Caused by Kerstersia gyiorum

Which trial do we need? Percutaneous mechanical aspiration versus medical management alone for treatment of right-sided valvular infective endocarditis

The Emperor’s New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE)

Practical application of good participatory practices for trials of emerging pathogens: Developing materials for use in ACTIV-3, -3b, and ACTIV-associated COVID-19 trials

Persistent Methicilin-Resistant Staphylococcus aureus Bacteremia: Resetting the Clock for Optimal Management

Ceftobiprole for Staphylococcus aureus Bacteremia. Reply

Antiplatelet Therapy in Staphylococcus aureus Bacteremia: No Time Like the Past?

Determination of plasma protein binding of dalbavancin

Compiling Observational Research During a Pandemic: A Necessary Bridge

Infective endocarditis

Leadless pacemaker infective endocarditis: a case report and review of the literature

A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study)

Combination Therapy for MRSA Bacteremia: To ß or Not to ß?

Which trial do we need? Next-generation sequencing to individualize therapy in Staphylococcus aureus bacteraemia

External Validation of the 2023 Duke–International Society for Cardiovascular Infectious Diseases Diagnostic Criteria for Infective Endocarditis

Improving Traditional Registrational Trial End Points: Development and Application of a Desirability of Outcome Ranking End Point for Complicated Urinary Tract Infection Clinical Trials

Clinical outcomes in patients with piperacillin/tazobactam-non-susceptible but ceftriaxone-susceptible E. coli or K. pneumoniae bloodstream infection

Suchergebnisse filtern